Jeong, Woondong

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 167

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 159

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies

Jeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer

Heterocyclic Compound Synthesis and BioactivitySynthesis and Characterization of Heterocyclic Compounds

Cited by 59